• No results found

University of Groningen Neuroendocrine tumors; measures to improve treatment and supportive care de Hosson, Lotte Doortje

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Neuroendocrine tumors; measures to improve treatment and supportive care de Hosson, Lotte Doortje"

Copied!
6
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Neuroendocrine tumors; measures to improve treatment and supportive care

de Hosson, Lotte Doortje

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from

it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

de Hosson, L. D. (2019). Neuroendocrine tumors; measures to improve treatment and supportive care.

Rijksuniversiteit Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Neuroendocrine tumors;

Measures to improve treatment and supportive care.

(3)

Neuroendocrine tumors; Measures to improve treatment and supportive care Lotte D. de Hosson

PhD dissertation, University of Groningen, the Netherlands

Layout by: XML 2 Publish Printing by: Gildeprint, Enschede

ISBN: 978-94-034-1443-0

ISBN (electronic version): 978-94-034-1442-3

© Copyright 2019 – Lotte D. de Hosson, Groningen, the Netherlands

All right reserved. No part of this thesis may be reproduced, stored in a retrieval or transmitted in any form or by any means, without prior permission of the author or, when appropriate of the publisher of the published articles.

Printing of this thesis was financially supported by the Stichting Werkgroep Interne Oncologie, Rijksuniversiteit Groningen, Universitair Medisch Centrum Groningen.

(4)

Neuroendocrine tumors; Measures

to improve treatment and

supportive care

Proefschrift

ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen

op gezag van de

rector magnificus prof. dr. E. Sterken en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op woensdag 20 februari 2019 om 16.15 uur

door

Lotte Doortje de Hosson

geboren op 15 januari 1985 te Maurik

(5)

Promotor

Prof. dr. E.G.E. de Vries

Copromotor

Dr. A.M.E. Walenkamp

Beoordelingscommissie

Prof. dr. W.W. Herder Prof. dr. H. Hollema Prof. dr. G.A.P. Hospers

Paranimfen

Kim J.H.A. de Hosson Iris I.C. Kok

(6)

Contents

Chapter 1 General introduction and outline of the thesis 6

Chapter 2 Clinical benefit of systemic treatment in patients with advanced

pancreatic and gastro-intestinal neuroendocrine tumors according to ESMO-MCBS and the Net Health Benefit of ASCO revised framework.

16

L.D. de Hosson, L.M. van Veenendaal, Y. Schuller, W.T. Zandee, W.W. de Herder, M.E.T. Tesselaar, H.J. Klümpen, A.M.E. Walenkamp.

Chapter 3 a) Web-based tailored information and support for patients with a

Neuroendocrine tumor; WIN-pilot. 40

G. Bouma, L.D. de Hosson, C. E. van Woerkom, H. van Essen, G.H. de Bock, J.M. Admiraal, A.K. L. Reyners, A. M. E. Walenkamp.

b) Web-based tailored nformation and support for patients with a

Neuroendocrine tumor; WIN-study 58

L.D. de Hosson*, G. Bouma*, J. Stelwagen, H. van Essen, G.H. de Bock, D.J.A. de Groot, E.G.E. de Vries, A.M.E. Walenkamp.

Chapter 4 Towards optimal personalized diet and vitamin supplementation

in NET patients; DIVIT-pilot. 78

L.D. de Hosson, J. Stelwagen, G. Bouma, B. Sijtema, S, Huitema, H.J.R. van Faassen, G.H. de Bock, D.J.A. de Groot, M.J.E. Campmans-Kuijpers, I.P. Kema, E.G.E. de Vries, A.M.E. Walenkamp.

Chapter 5 Heterogeneity in neuroendocrine tumor lesions visible with

[18F]FDOPA PET/CT 88

L.D. de Hosson, A.M. van der Loo- van der Schaaf, R. Boellaard, J. H. van Snick, E.G.E. de Vries, A. H. Brouwers, A.M.E. Walenkamp.

Chapter 6 Reasons for the cold immune microenvironment of

neuroendocrine tumours. 108

L.D. de Hosson*, G. Bouma*, G. Kats-Ugurlu, M. Bulthuis, E.G.E. de Vries, M. van Faassen, I.P. Kema, A.M.E. Walenkamp.

Chapter 7 Summary and future perspectives 126

Appendix Dutch summary, Nederlandse samenvatting 143

Referenties

GERELATEERDE DOCUMENTEN

background activity with PET scans and investigated if tumor lesions with substantially higher [ 18 F]FDOPA uptake could be identified in patients with SI-NET.... Materials

In patients with metastatic urothelial carcinoma, lack of response to immune checkpoint blockade is associated with increased TGF-β signalling in fibroblasts in the

Potentially, in patients with carcinoid syndrome [ 18 F]FDOPA PET scans can be used to select lesions with substantially higher [ 18 F]FDOPA uptake for local treatment like

Daarnaast hebben we gekeken of we op 18Fluorine-L-dihydroxyphenylalanine (18F-DOPA) PET scans van patiënten met een NET laesies met hoge opname konden worden geïdentificeerd,

Lieve vriendinnen, lieve Marlies, hartelijk dank voor alle keren dat je heerlijk voor me hebt gekookt, een rondje mee ging hardlopen en de kopjes (of bierpul met) thee waarbij

Clinical benefit of systemic treatment in patients with advanced pancreatic and gastro intestinal neuroendocrine tumors according to ESMO-MCBS and ASCO framework.. randomized

Bij patiënten met gemetastaseerde neuro-endocriene tumoren van de dunne darm is er heterogene 18 F-DOPA tracer opname tussen tumor laesies binnen een patiënt. Met 18 F-DOPA

Eligible studies were randomized controlled trials (RCT) and non- randomized controlled trials (CT), performed in adult cancer patients (≥18 years), comparing quantitative